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Myocilin and optineurin are two genes linked to glaucoma, a major blinding disease characterized by
progressive loss of retinal ganglion cells and their axons. This review describes the characteristics of
myocilin and optineurin protein products and summarizes the consequences of ectopically expressed
wild-type and mutant myocilin and optineurin in trabecular meshwork and/or neuronal cells. Myocilin
and optineurin exhibit differential characteristics and have divergent functional consequences. They
contribute to the development of glaucoma probably via distinct mechanisms.
Copyright  2011, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Glaucoma is one of the leading causes of irreversible blindness
worldwide. This disease is characterized by progressive loss of
retinal ganglion cells (RGCs) and accompanying axons. Primary
open-angle glaucoma (POAG), the most common form of glaucoma,
is frequently associated with increased intraocular pressure (IOP).
The IOP is controlled by a balance between the production and
outﬂow of the aqueous humor contained in the anterior chamber.
The trabecular meshwork (TM), a specialized tissue, is the major
site for regulation of the aqueous humor outﬂow.1,2
Studies over the past decades have revealed that POAG is
genetically heterogeneous, caused by several susceptibility genes
and environmental factors.3,4 To date, a total of 15 chromosomal
loci have been mapped and designated as GLC1A to GLC1O.37 Four
candidate genes have been identiﬁed that include myocilin as the
GLC1A,6 optineurin as the GLC1E,7 WDR36 as the GLC1G,3,4 and
neurotrophin-4 as the GLC1O3,4 gene.
Myocilin is the ﬁrst identiﬁed gene for both juvenile- and adult-
onset POAG.6 More than 70 myocilin mutations have been found in
several families.3,5 Glaucoma patients with myocilin mutation tend
to have high IOP.5 Among the myocilin mutations, the Gln368Stop
(Q368X) mutation is the most frequent8 and the Pro370Leu (P370L)
mutation is responsible for one of the most severe glaucoma
phenotypes.
Optineurin is a gene that links principally to normal tension
glaucoma (NTG), a subtype of POAG.7 Optineurin mutations areces, University of Illinois at
hicago, IL 60612, USA.
e Ophthalmologic Society of Taiwanoted to vary with ethnic background.9 The Glu50Lys (E50K)
mutation, found in Caucasian and Hispanic populations,9 seems to
be associated with a more progressive and severe disease in NTG
patients.102. Gene structure and expression
The myocilin gene contains three exons and two introns that
span 17 kb pairs.11 The protein product encoded by the human
gene contains 504 amino acids. There is a hydrophobic signal
peptide sequence (amino acids or aa 1e32) and non-musclemyosin-
like domain near the amino (N)-terminus and an olfactomedin-like
domain (aa 326e501) at the carboxyl (C)-terminus. The N-terminus
has two initiation sites. Within the myosin-like domain, there are
leucine zipper motifs within two coiled-coil regions (aa 74e110
and aa 118e186).11,12 The leucine zipper and the olfactomedin
domains are well conserved across species. At the secondary level,
the N-terminal region is primarily a-helical and the C-terminal
consists mostly of b-strands.13 In glaucoma patients, most of the
myocilin mutations are mapped to the third exon of the gene
within the C-terminal olfactomedin domain.
The expression of myocilin is mainly in the eye, but it has also
been observed in several other tissues in the body including the
skeletal muscle and brain. In the eye, myocilin is seen in many
tissues such as the sclera, ciliary body and the optic nerve head,14
although its expression is the highest in the TM.
The human optineurin gene has a total of 16 exons; the ﬁrst 3 are
non-coding and the remaining 13 exons code for a 577-amino acid
protein that contains multiple coiled-coil domains and a C-terminal
zinc ﬁnger.15,16 The optineurin protein from different species hasn. Published by Elsevier Taiwan LLC. All rights reserved.
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residue is conserved in mouse, rat, chicken and cow. Optineurin is
also ubiquitously expressed in non-ocular tissues such as the heart
and brain, and in ocular tissues including the retina, trabecular
meshwork and non-pigmented ciliary epithelium. In the retina,
RGCs are immunolabeled with high intensity.15,16
3. Protein characteristics
Myocilin was initially identiﬁed as a protein secreted into the
media of TM cultures after induction with glucocorticoids such as
dexamethasone (DEX).12 One unique feature is that myocilin
expression is highly upregulated by DEX in TM cells but not in other
cell types such as corneal ﬁbroblasts.11,17 Containing a signal peptide
sequence at the N-terminus, myocilin is, at least in part, secreted via
the traditional secretory pathway. Myocilin has additionally been
shown to associate with exosome-like vesicles andmay also use this
alternative mechanism to be released from the cell.11
Myocilin has been shown to be a glycoprotein, N-glycosylated at
amino acid residues 57e59 (Asn-Glu-Ser).11 On Western blots, it is
seen as 53e57 kDa doublet bands although some antibodies also
yield a 66-kDa protein band. When subjected to membrane protein
extraction, myocilin in TM cell lysates distributed largely in the
hydrophobic fraction in association with membranes (Fig. 1). The
myocilin protein has also been reported to be cleaved into a 20-kDa
N-terminal fragment and a 35-kDa C-terminal fragment both
in vitro and in vivo. The proteolytic processing of myocilin is sug-
gested to have a role in regulating its molecular interactions.18
Myocilin interacts with itself at sites of the leucine zipper/
coiled-coil domain to form dimers and possibly multimers.11,19,20
It also interacts with several proteins including ﬂotillin-1 (a struc-
tural protein of lipid rafts), optimedin, extracellular proteins such as
ﬁbronectin and ﬁbrillin-1, as well as matricellular proteins hevin
and SPARC.11,18
Optineurin, by contrast, is not secreted.21 It is neither N- nor
O-glycosylated but is serine- and tyrosine-phosphorylated.22
Optineurin is shown to be, exclusively, a hydrophilic, cytosolic
protein.22 It possesses a ubiquitin-binding domain, is ubiquitinated
and is processed through the ubiquitineproteasome pathway.22,23
By native blue gel electrophoresis, optineurin is found to be
capable of forming 420 kDa homo-oligomers, which, based on the
67-kDa monomer size, is estimated to be hexamers.22 Furthermore,
optineurin interacts and associates with Rab8, myosin VI and
transferrin receptor,22,24 either singly or in combination, to form
supermolecular complexes with sizes larger than 400 kDa.22
Optineurin has also been shown to interact with transcription
factor IIIA,25 huntingtin,26 metabotropic glutamate receptor27 andFig. 1. Western blot analysis for myocilin in hydrophilic and hydrophobic fractions of
human TM cell lysates. Total proteins in TM lysates were subjected to membrane
protein extraction followed by Western blotting. The hydrophobic fraction contained
membrane proteins and the hydrophilic fraction contained predominantly non-
membrane cytosolic proteins. Myocilin (MYOC) in total cell lysates was detected
largely in the hydrophobic fraction, although a small portion was also seen in the
cytosolic, hydrophilic fraction. GM130, a Golgi marker used as a membrane protein
positive control, was detected exclusively in the hydrophobic fraction.TANK-binding kinase 1 (TBK1).28 It shares 53% amino acid
homologywith NEMO (NF-kB essential modulator) and is identiﬁed
as a NEMO-related protein.29 Optineurin expression is upregulated
by tumor necrosis factor-a (TNFa)15 and interferon and its phos-
phorylation is induced upon phorbol 12-myristate 13-acetate
stimulation.294. Localization
Myocilin protein is localized to both intracellular and extracel-
lular sites in TM cells. Immunoﬂuorescence has shown that the
intracellular form of myocilin is diffusely distributed in the cyto-
plasm including perinuclear regions.11,17 Subcellular fractionation
and/or immunoelectron microscopy indicated that intracellular
myocilin in TM cells is associated not only with endoplasmic
reticulum, Golgi apparatus, vesicles but also withmitochondria.11,30
Immunogold labeling documented the extracellular localization of
myocilin.11,31,32 It is intriguing that, in TM tissues, myocilin is mainly
associated with microﬁbrillar architecture in sheath-derived pla-
ques where pathologic changes have been reported to occur in the
eyes of POAG patients.32
Optineurin also has a diffuse, cytoplasmic distribution but
a proportion of the protein is associated with the Golgi apparatus.21
As optineurin is a cytosolic protein not associated withmembranes,
the optineurineGolgi association is probably indirect via interac-
tions of other Golgi-associated proteins such as Rab8.225. Consequences of overexpression and mutation and/or
possible functional roles
5.1. Deadhesive activity, Rho inactivation, mitochondrial
association and inhibition on neurite outgrowth: Myocilin
phenotype
The extracellular myocilin was demonstrated to be a very poor
substrate for TM cells.33 It blocks the TM attachment to ﬁbronectin,
retards migration, causes a dramatic reduction in actin stress ﬁbers
and focal adhesions,33,34 and triggers TM cells to assume a stellate
morphology with microspikes.34 Myocilin has been shown to
interact with ﬁbronectin via the heparin (Hep) II domain.35,36 This
domain, along with the Arg-Gly-Asp site, is where ﬁbronectin is
linked to the actin cytoskeleton, transducing signals from the
exterior to the interior of the cells. The ﬁbronectineTM cell inter-
action is possibly mediated via binding of myocilin to the Hep II
domain.36 Puriﬁed recombinant myocilin protein has also been
more recently noted to be a modulator of Wnt signaling.37
Overexpressing wild-type or full-length myocilin intracellu-
larly38 by transfection or by protein transduction39 in TM cells
results in an alteration in actin architecture, similar to that seen
with the extracellular form of myocilin. Key ﬁndings include a loss
of actin stress ﬁbers and vinculin-positive focal adhesions, and
a reduction in cell adhesion to ﬁbronectin, vitronectin and collagen
types I and IV.40 The ﬁbronectin deposition is diminished and the
trypsinization time needed to round up or suspend TM cells from
plates is signiﬁcantly shorter for myocilin transfectants than that
for mock controls, signifying compromised cellematrix adhesive-
ness.40 Myocilin therefore appears to possess a deadhesive activity,
capable of changing TM cells in culture from a state of strong
adherence, containing robust focal adhesions and actin-containing
stress ﬁbers, to a state of compromised adhesiveness. The dead-
hesion process, on a long-term chronic basis, may render TM cells
vulnerable. Myocilin-overexpressing cells have been shown to
display an increased susceptibility to apoptotic challenge.38 It is
speculated that cell vulnerability, in conjunction with additional
Fig. 2. PKA activity in optineurin-expressing cells. Human TM cells were transfected
with pEGFP-N1 (GFP) or pOptineurin-GFP (OPTN-GFP) for 24 hours. Equal amounts of
protein lysates were subjected to PKA assays. Positive (þ) and negative (e) controls
were included. The non-phosphorylated (upper band, arrow) and the phosphorylated
(lower band, arrowhead) substrates were resolved on agarose gels. The PKA activity in
optineurin transfectants, indicated by the level of the phosphorylated substrate and
determined by densitometric analyses, was similar to that in the GFP control.
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comatous conditions.
When treated with lysophosphatic acid, a Rho stimulator, the
ﬁbronectin deposition in myocilin transfectants was enhanced,
suggesting a role of small GTPase Rho family in the myocilin
phenotype.40 Subsequent pull-down assays indeed verify that the
level of GTP-bound or active RhoA inmyocilin transfectants is lower
than that in controls. Further assays, in accordance with the notion
that the regulation of Rho function represents a major target for
protein kinase A (PKA) in cytoskeletal modulation, disclose that
along with RhoA inactivation, the adenosine 30,50-cyclic mono-
phosphate level and the PKA activity are enhanced upon myocilinFig. 3. Foci formation in optineurin-expressing Neuro2a neuronal cells. The cells were t
pOptineurin-EGFP (B and D) to express wild-type optineurin-GFP. When transfected with
When transfected with pOptineurin-EGFP, diffuse green ﬂuorescence was seen in the cytop
were additionally noted in the perinuclear region. The foci were observed in cells withouttransfection. Inhibition of PKA by inhibitor H-89 in myocilin-
transfected cells prevents, at least partially, the stress ﬁber disso-
lution. Time lapse video microscopy corroborates that both the
H-89 treatment and co-transfectionwith constitutively active RhoA
delay the rounding up or prolong the trypsinization time of
myocilin-green ﬂuorescence protein (GFP)-expressing cells.40
The association of myocilin with mitochondria was examined
by mitochondrial import assays.41 Cell free-translated myocilin
was incubated with isolated mitochondria and the assays revealed
that myocilin is robustly imported into the mitochondria isolated
from TM cells, but only minimally into those from corneal ﬁbro-
blasts and mouse liver. The myocilin imported into TM mito-
chondria is mostly targeted to the membranes. When upregulated
or overexpressed, myocilin induces a drop of the mitochondrial
membrane potential, indicative of mitochondrial depolarization
or dysfunction.41
The effect of myocilin on neurite outgrowth was investigated.42
Neuronal PC12 and RGC5 cells were transfected to express
myocilin-GFP and allowed to differentiate. Whereas the mock-
transfected control cells produced long neurites, the length of
neurites in wild-type myocilin-transfected cells was reduced to
nearly half of that of controls. The number of neurites was likewise
decreased. Myocilin mutant P370L and Q368X constructs also eli-
cited inhibitory effects on neurite outgrowth, comparable to that
seen with the wild-type myocilin.42
Optineurin transfection, by contrast, has no effect on the actin
structure, focal adhesion formation or trypsin sensitivity of the
cells.40 The PKA activity was also unaltered (Fig. 2).ransfected for 20 hours with pEGFP-N1 (A and C, mock control) to express GFP, or
pEGFP-N1, green ﬂuorescence was observed in the entire cells including the nucleus.
lasm of Neuro2a cells. Strikingly, bright granular or punctuate structures termed foci
(B) and with (D) neuronal morphology showing neurite extensions. Scale bar: 10 mm.
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dria.41 Neither overexpression nor mutation of optineurin results in
any compromise of the mitochondrial membrane potential (data
not shown). There was also no inhibitory effect on the neurite
outgrowth.42
5.2. Golgi fragmentation, impaired transferrin uptake, NF-kB
pathway and inﬂammation regulation, and cell death: Optineurin
phenotype
When transfected to express optineurin-GFP fusion protein,
diffuse green ﬂuorescence is seen in the cytoplasm of human
retinal pigment epithelial (RPE),21 RGC5,22 PC1242 and mouse
neuroblastoma Neuro2a (Fig. 3) cells. Notably, bright granular or
punctuate structures are also observed in perinuclear regions of allFig. 4. The Golgi integrity in cells expressing wild-type and mutant myocilin. Inducible, stab
hours. Upon treatment, the cells were induced to express wild-type myocilin-GFP (MYOCWT;
L), or wild-type optineurin-GFP (OPTN; M, N, O). Immunoﬂuorescence staining for Golgi m
marked by GFP green ﬂuorescence, the nuclei were stained with DAPI in blue and Golgi s
Fragmentation of the Golgi apparatus is seen in cells expressing optineurin-GFP (as a posi
myocilin-GFP. Scale bar: 10 mm.cell types. These structures, termed foci, are dynamic. Visualized by
live cell imaging, theymove around in both short and long ranges.22
Subsequent experimentation using nocadazole proved that the
formation of optineurin foci is microtubule-dependent.21,22 Such
foci are likewise formed in cells after transfection to overexpress
mutant E50K optineurin-GFP. The number and the size of the E50K-
GFP foci are even greater than those of the wild type.21
Golgi fragmentation was noted upon optineurin overexpression
when the cells were immunostained with Golgi marker GM130 or
Golgin97. The degree of fragmentation is also more severe in E50K
transfectants than the wild type.21,22
Optineurin, as discussed above, is known to interact with Rab8,
myosin VI, huntingtin and transferrin receptor; all are players in
membrane trafﬁcking. To determine the role of optineurin in protein
trafﬁcking, transferrin uptake, an indicator of receptor-mediatedle RGC5 cells were untreated (Non-Induced; A, B, C) or treated with doxycycline for 24
D, E, F), P370L myocilin-GFP (MYOCP370L; G, H, I), Q368X myocilin-GFP (MYOCQ368x; J, K,
arker, GM130, was performed. The myocilin- or optineurin-GFP-expressing cells were
taining in both induced (green) and non-induced (non-green) cells was seen in red.
tive control, N) but not in those expressing wild-type and P370L and Q368X mutant
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transfection to overexpress wild-type and E50K optineurin. Results
obtained indicated that the transferrin uptake was signiﬁcantly
decreased in optineurin-expressing cells.43 The reduction was
observed from the initial 2- and 5-minute time points. Co-
transfection with transferrin receptor, but not Rab8 or myosin VI,
construct rescued the optineurin inhibitory effect. The ectopic
expression of optineurin caused transferrin receptor to colocalize
with the foci. Surface biotinylation experiments further showed that
the surface level of transferrin receptor was lowered, presumably
leading to an impeded transferrin uptake.43 The optineurin pheno-
type is probably mediated by the interaction between optineurin
and transferrin receptor molecules. The E50K mutation, compared
with the wild type, yielded a more pronounced impairment in the
transferrin uptake.43
Optineurin, sharing an amino acid homology with NEMO, is
demonstrated to be a negative regulator of NF-kB.44,45 It is well
known that transcription factor NF-kB is retained in an inactive form
in the cytoplasm. Upon activation by TNFa, signaling intermediates
such as RIP (receptor interacting protein) are recruited to the TNF
receptor, resulting in activation of the IkB kinase (IKK) complex. The
inhibitory proteins of the IkB family are then degraded and NF-kB is
translocated to the nucleus to trigger gene regulation. NEMO is the
catalytic unit known as IKKg of the IKK complex. Optineurin
competes with NEMO for binding to ubiquitinated RIP to inhibit
TNFa-induced NF-kB activation. There appears to be a negative
feedback loop; optineurin gene expression is elevated by treatment
of TNFa via the NF-kB pathway, and the optineurin induced in turn
inhibits NF-kB activation, suggesting a physiological role for opti-
neurin in dampening TNFa signaling.44,45
Via interaction with TBK1, optineurin has been shown to inhibit
virus-triggered interferon-b induction.46 Similar to NF-kB signaling,
the ubiquitin binding domain of optineurin appears to be essential
for regulation of the antiviral response.46 The role of optineurin
may therefore be expanded from a modulator of TNFa signaling to
a broad-spectrum negative regulator of inﬂammation.
Cell death ensued following optineurin overexpression.42 Cell
loss is, at least in part, due to increased apoptosis.42 As is seen with
other optineurin phenotypes, cell loss is also more pronounced in
E50K-expressing cultures.
As the E50Kmutation generates much striking effects compared
with the wild-type optineurin, this mutation is apparently a gain-
of-toxicity mutation. Defective trafﬁcking, deregulated NF-kB
signaling, along with fragmentation of the Golgi complex and
induction of apoptosis, are speculated to be the underlying bases
why E50K mutation renders the patients predisposed to glaucoma
pathology.
Overexpression of wild-type myocilin results in diffuse distri-
bution but little foci are observed in TM or RGC5 cells. No frag-
mentation of the Golgi is detected and the apparatus remains intact
regardless of whether the cells were transfected with wild-type or
mutant (P370L and Q368X) myocilin (Fig. 4).
Unlike optineurin, wild-typemyocilin does not affect transferrin
uptake or its kinetics.43 In addition, in contrast to optineurin,
overexpression of wild-type myocilin does not invoke apoptosis in
TM cells.41 However, treatment of anti-Fas does induce a signiﬁ-
cantly higher level of apoptosis in myocilin-expressing cells
compared with mock or non-transfected controls.29 Myocilin
overexpression appears to sensitize cells to apoptotic challenges.
Of note is that P370L and Q368X myocilin mutants do trigger
cell death.42 These mutants are not secreted.47 They are retained in
the cells and have been shown to form aggregates to cause endo-
plasmic reticulum stress.48
It is unknown whether myocilin plays a role in either NF-kB
signaling/regulation or antiviral response.6. Conclusions
Myocilin mutations are typically associated with high IOP cases
and optineurin mutations are associated with NTG. As reviewed
above, these two glaucoma genes are different, exhibiting dissim-
ilar characteristics and eliciting differential effects on signal
transduction, neurite outgrowth and protein trafﬁcking process.
The dissimilarity implicates that myocilin and optineurin have
different functional roles and that they contribute to the develop-
ment of neurodegenerative glaucoma via distinct mechanisms.
Continued efforts directed at unraveling of such mechanisms are
likely to be fruitful, providing further insights into the molecular
bases involved in the pathogenesis of glaucoma.
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